FINWIRES · TerminalLIVE
FINWIRES

TransAlta社、マイク・ポリテスキ氏をCFOに任命

-- TransAlta(TA.TO)は月曜日、マイク・ポリテスキ氏を財務担当上級副社長兼最高財務責任者(CFO)に任命したと発表した。就任は5月1日付。 また、グラント・アーノルド氏を成長担当上級副社長兼最高商務責任者(CCO)に任命した。就任は5月6日付。 TransAltaによると、これらの人事は、現上級副社長兼CFOのジョエル・ハンター氏が4月30日付で社長兼最高経営責任者(CEO)に就任することに伴うもの。 現社長兼CEOのジョン・コウシニオリス氏は4月30日付で退任する。 ポリテスキ氏は、資本市場、財務戦略、リスク管理、財務、財務報告、税務など、25年以上の経験を持つ。直近では、Veren社で財務担当上級副社長兼財務責任者を務めていた。 一方、アーノルド氏は、発電およびエネルギー分野で30年以上のリーダーシップ、商業、技術経験を持つ。BluEarth Renewables社で社長兼CEOを務めた。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA